Ipilimumab Plus Nivolumab Promising for Patients with Metastatic or Unresectable Angiosarcoma


A prospective, open-label, multicenter, phase 2 trial of ipilimumab (Yervoy) plus nivolumab (Opdivo) for patients with metastatic or unresectable angiosarcoma indicated that the combination was well-tolerated, warranting further investigation of the combination for this patient population.1

This study was part of a path-breaking clinical trial called DART, short for Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors.2 Launched in 2017, DART uses an innovative “basket” design to test the effectiveness of the ipilimumab and nivolumab combination in a variety of rare tumor types. Through DART, the drug combination has completed testing in 36 cohorts of rare cancer patients, with another 12 cohorts still taking the drugs, and 4 cohorts temporarily closed for data analysis.

The results observed in patients with metastatic or unresectable angiosarcoma, shared in a virtual oral presentation at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting, demonstrated an objective response rate (ORR) of 25% in angiosarcoma regardless of primary site, with 3 of 5 patients with cutaneous tumors of the scalp or face responding. Importantly, this study is the first to provide evidence that immunotherapies can treat angiosarcoma.

“These results open a new way to treat angiosarcoma – with immunotherapy,” Michael Wagner, MD, of the University of Washington, the Fred Hutchinson Cancer Research Center, and the Seattle Cancer Care Alliance, said in a press release. “At [SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute’s (NCI) Division of Cancer Diagnosis and Treatment], we’re planning a larger follow-up study to see if this combination can work as a first line of treatment.”

In this ongoing study, participants with metastatic or unresectable angiosarcoma were administered 1 mg/kg of ipilimumab intravenously (IV) every 6 weeks plus 240 mg of nivolumab by IV every 2 weeks. The primary end point is ORR as assessed by RECIST v1.1, including measurable cutaneous disease that can be followed by photography. Key secondary end points include progression-free survival (PFS), overall survival (OS), stable disease at 6 months, and toxicity.

Of note, a two-stage design was used with 6 patients in the first stage and an additional 10 patients in the second stage for a total of 16 patients with angiosarcoma enrolled. Median age was 68 years (range, 25-81 years). Median number of prior lines of therapy was 2 (range, 0-5).

At the data cutoff, 9 patients had cutaneous primary tumors of any cutaneous site and 7 had non-cutaneous primary tumors. The ORR for all patients was 25%. Moreover, subgroup analysis also revealed that 60% of patients with primary cutaneous tumors of the scalp or face had a confirmed objective response. The 6-month PFS was 38%.

Regarding safety, 75% of patients experienced an adverse event (AE), and 25% experienced a grade 3 or 4 AE. Further 68.8% experienced an immune related AE (irAE), and 2 (12.5%) developed grade 3 or 4 irAEs.

The grade 3 or 4 irAEs observed were alanine aminotransferase (ALT) and aspartate aminotransferase (AST) increase, as well as diarrhea. There were no grade 5 toxicities reported.

References:

1. Wagner M, Othus M, Patel S, et al. A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). Presented at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting. Abstract #: 795.

2. Rare Angiosarcomas Respond to Immunotherapy [news release]. SWOG Cancer Research Network. Published November 13, 2020. Accessed November 16, 2020. https://www.swog.org/news-events/news/2020/11/13/rare-angiosarcomas-respond-immumotherapy



Source link

Get in Touch

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Nov. 25 data: Utah counts 26 deaths from COVID-19 heading into Thanksgiving weekend

SALT LAKE CITY (KUTV) — Heading into a Thanksgiving weekend Utah officials fear may be a super-spreader holiday, the state counted 26 new COVID-19...

Diabetes: Facts you should know in the era of COVID-19

Sponsored by:As the United States surpasses 250,000 deaths from COVID-19, it’s worth noting that people with...

Gut hormones’ regulation of fat production abnormal in obesity, fatty liver disease — 02xl

Gut hormones play an important role in regulating fat production in the body. One key hormone, released a few hours after eating, turns off...

Get in Touch

0FansLike
2,452FollowersFollow
0SubscribersSubscribe

Latest Posts

Nov. 25 data: Utah counts 26 deaths from COVID-19 heading into Thanksgiving weekend

SALT LAKE CITY (KUTV) — Heading into a Thanksgiving weekend Utah officials fear may be a super-spreader holiday, the state counted 26 new COVID-19...

Diabetes: Facts you should know in the era of COVID-19

Sponsored by:As the United States surpasses 250,000 deaths from COVID-19, it’s worth noting that people with...

Gut hormones’ regulation of fat production abnormal in obesity, fatty liver disease — 02xl

Gut hormones play an important role in regulating fat production in the body. One key hormone, released a few hours after eating, turns off...

Trump administration makes last-ditch effort to deregulate school nutrition standards

The latest provisions will likely please school food administrators, who have called for looser nutrition regulations in the past, USDA acknowledged in a news...

Coronavirus cases surpass 60M worldwide, Johns Hopkins data shows

Fauci touts safety of vaccine development process, says Americans need to continue public health measures NIAID Director Fauci said Nov. 19 that...
Supportscreen tag
%d bloggers like this: